LL-37
Also known as: Cathelicidin, hCAP-18 active peptide, CAMP peptide, Human Cathelicidin Antimicrobial Peptide
Grey-Market Compound. This compound is not approved by the FDA or any major regulatory authority. No established regimen exists. Products available outside of regulated channels lack standardized manufacturing, quality control, and potency verification. Consult a qualified clinician. Research-only risks apply.
Overview
Clinical Summary
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid peptide cleaved from the precursor protein hCAP-18. It is a key component of innate immunity with broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses. Beyond direct antimicrobial action, LL-37 plays roles in wound healing, angiogenesis, and immunomodulation. It is produced by neutrophils, epithelial cells, and macrophages at sites of infection and tissue injury. Preclinical data support its role in biofilm disruption, wound re-epithelialization, and immune cell chemotaxis. No injectable formulation has completed human clinical trials for systemic use. Grey-market injectable LL-37 is used for immune support and infection management without clinical trial evidence for these applications.
Plain Language Summary
LL-37 is a natural peptide made by your immune system to fight infections. It kills bacteria, fungi, and some viruses, and also helps wounds heal. Scientists are interested in it because it can break apart bacterial biofilms (protective layers that bacteria form to resist treatment). While it plays an important role in the body naturally, injectable versions sold through grey-market suppliers have not been tested in human clinical trials, so their safety and effectiveness when used this way are unproven.
Mechanism of Action
LL-37 exerts antimicrobial effects through multiple mechanisms. It disrupts microbial membranes via electrostatic interactions between its cationic amphipathic structure and negatively charged bacterial membranes, leading to pore formation and cell lysis. At sub-lethal concentrations, LL-37 inhibits biofilm formation by reducing bacterial attachment to surfaces, suppressing quorum sensing, and stimulating bacterial surface motility. Beyond antimicrobial actions, LL-37 promotes wound healing by transactivating the epidermal growth factor receptor (EGFR), stimulating keratinocyte migration and proliferation. It also serves as a chemoattractant for neutrophils, monocytes, and T cells through formyl peptide receptor-like 1 (FPRL1) activation, and promotes angiogenesis through VEGF-independent pathways.
Evidence Summary
Evidence for LL-37 is predominantly preclinical. Vandamme et al. (2012) provided a comprehensive review of its antimicrobial spectrum and immunomodulatory properties. Heilborn et al. (2003) demonstrated that LL-37 promotes wound re-epithelialization through EGFR transactivation and that chronic wounds are deficient in LL-37. Overhage et al. (2008) showed LL-37 disrupted Pseudomonas aeruginosa biofilms at sub-MIC concentrations. Small clinical studies of topical LL-37 for wound healing and venous leg ulcers have shown preliminary promise, but no large-scale RCTs exist. No human clinical trial data support injectable systemic use for immune enhancement or infection management.
Safety Profile
No formal safety data exist for injectable LL-37 in humans. LL-37 is naturally present in human tissues and body fluids, but pharmacological doses delivered systemically may have effects not seen at physiological concentrations. At high concentrations, LL-37 can be cytotoxic to host cells (particularly erythrocytes and epithelial cells) due to its membrane-disrupting mechanism. LL-37 has been implicated in the pathogenesis of psoriasis (forming complexes with self-DNA that activate plasmacytoid dendritic cells via TLR9) and rosacea. Grey-market injectable products carry risks related to sterility, purity, endotoxin contamination, and dosing accuracy.
Contraindications
- Known hypersensitivity to LL-37 or cathelicidin-derived peptides
- Active psoriasis (LL-37 may exacerbate via TLR9-mediated autoimmune pathways)
- Rosacea (LL-37 is implicated in rosacea pathogenesis)
- Pregnancy and breastfeeding (no safety data for pharmacological doses)
Adverse Events
- No systematic human adverse event data for injectable use
- Injection site reactions (reported anecdotally)
- Potential hemolysis at high concentrations (preclinical observation)
- Theoretical risk of autoimmune activation (psoriasis, LL-37-DNA complex formation)
Interactions
- No formal drug interaction studies conducted
- May have additive or synergistic effects with conventional antibiotics (preclinical data)
- Potential interaction with immunosuppressive agents (opposing mechanisms)
- Heparin and other polyanionic molecules may neutralize LL-37 activity through charge-based binding
Regulatory Notes
LL-37 has no regulatory approval for therapeutic use in any jurisdiction. It is a research peptide that has not entered formal clinical development as an injectable drug. Topical LL-37 formulations have been studied in early-phase wound healing trials but none have received regulatory approval. Grey-market injectable products are not manufactured under GMP conditions. The FDA has not specifically addressed LL-37 in compounding guidance.
Monitoring Considerations
No evidence-based monitoring guidelines exist. Clinicians may consider monitoring for signs of injection site reactions, complete blood count (given theoretical hemolysis risk at high doses), inflammatory markers, and skin assessment for psoriasiform or rosacea-like eruptions. If used for infection management, appropriate microbiological culture and sensitivity testing should guide treatment alongside, not be replaced by, LL-37.
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
LL-37 is typically supplied as a lyophilized powder. It should be reconstituted with sterile water or bacteriostatic water. The peptide is susceptible to proteolytic degradation and may adsorb to glass and plastic surfaces due to its amphipathic nature. Reconstituted solutions should be stored at 2 to 8 degrees C and used promptly. Low-bind tubes or vials are recommended to minimize surface adsorption losses. Formal stability data for injectable formulations are not publicly available.
References
- 1review
LL-37, the Only Human Member of the Cathelicidin Family of Antimicrobial Peptides
Vandamme D, Landuyt B, Luyten W, Schoofs L. (2012). Biochimica et Biophysica Acta
Key findings: Comprehensive review of LL-37 biology including broad-spectrum antimicrobial activity, immunomodulation, wound healing promotion, and angiogenesis. LL-37 disrupts bacterial membranes and biofilms.
Limitations: Review article. Most data from in vitro and animal studies.
- 2preclinical
LL-37 Promotes Wound Healing by Stimulating Keratinocyte Migration and Proliferation
Heilborn JD, Nilsson MF, Kratz G, et al. (2003). Journal of Investigative Dermatology
Key findings: LL-37 was upregulated in wound edge keratinocytes and promoted re-epithelialization through EGFR transactivation. Chronic wound fluid showed decreased LL-37 levels compared to acute wounds.
Limitations: In vitro and observational human tissue study. No controlled clinical trial.
- 3preclinical
The Human Cathelicidin LL-37 Disrupts Bacterial Biofilms
Overhage J, Campisano A, Bains M, et al. (2008). PLoS Pathogens
Key findings: LL-37 inhibited Pseudomonas aeruginosa biofilm formation at sub-MIC concentrations and disrupted preformed biofilms through multiple mechanisms including reduced bacterial attachment and stimulation of twitching motility.
Limitations: In vitro biofilm model. Effective concentrations in vivo remain uncertain.
View source
Last reviewed: 2024-12-20 | Version: 1 | Status: Published
More in Recovery
BPC-157
Body Protection Compound-157 · Bepecin · PL 14736 · PL-10
BPC-157 is a lab-made peptide based on a protein found naturally in stomach acid. In animal studies, it has shown remarkable healing properties for muscles, tendons, ligaments, the gut lining, and other tissues. However, there are very few human studies, so we do not know for certain whether these effects translate to people. It is popular among athletes and biohackers but is not an approved medication anywhere.
TB-500
Thymosin Beta-4 · TB4 · Timbetasin
TB-500 is a synthetic form of thymosin beta-4, a natural peptide your body already makes. It plays a role in healing wounds and reducing inflammation. Animal studies show it can speed up healing of muscles, tendons, and skin. Some human studies exist for eye and skin wound healing, but there is limited clinical evidence for the musculoskeletal uses that make it popular. It is not an approved medication.
GHK-Cu
Copper Peptide GHK · Glycyl-L-histidyl-L-lysine:copper(II)
GHK-Cu is a small peptide naturally present in your blood that binds to copper. It decreases as you age. Research suggests it plays a role in wound healing, collagen production, and skin repair. It is commonly found in anti-aging skincare products. Some people use injectable forms for broader anti-aging or recovery purposes, but clinical evidence for injectable use is limited.
Want to discuss this compound with a qualified physician?
The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.
Find a Verified Provider